156 related articles for article (PubMed ID: 30961642)
21. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.
Robinson MK; Hodge KM; Horak E; Sundberg AL; Russeva M; Shaller CC; von Mehren M; Shchaveleva I; Simmons HH; Marks JD; Adams GP
Br J Cancer; 2008 Nov; 99(9):1415-25. PubMed ID: 18841159
[TBL] [Abstract][Full Text] [Related]
22. Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas.
Friess H; Wang L; Zhu Z; Gerber R; Schröder M; Fukuda A; Zimmermann A; Korc M; Büchler MW
Ann Surg; 1999 Dec; 230(6):767-74; discussion 774-5. PubMed ID: 10615931
[TBL] [Abstract][Full Text] [Related]
23. Expression and differential signaling of heregulins in pancreatic cancer cells.
Kolb A; Kleeff J; Arnold N; Giese NA; Giese T; Korc M; Friess H
Int J Cancer; 2007 Feb; 120(3):514-23. PubMed ID: 17096356
[TBL] [Abstract][Full Text] [Related]
24. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.
Ishizawar RC; Miyake T; Parsons SJ
Oncogene; 2007 May; 26(24):3503-10. PubMed ID: 17173075
[TBL] [Abstract][Full Text] [Related]
25. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
[TBL] [Abstract][Full Text] [Related]
26. Combined evaluation of proliferation and apoptosis to calculate IC
Ekici Y; Yilmaz A; Kucuksezer UC; Gazioglu SB; Yamalioglu ZD; Gurol AO; Linn T; Tuncer FN
Med Oncol; 2021 Aug; 38(9):109. PubMed ID: 34357487
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-410 functions as a tumor suppressor by targeting angiotensin II type 1 receptor in pancreatic cancer.
Guo R; Gu J; Zhang Z; Wang Y; Gu C
IUBMB Life; 2015 Jan; 67(1):42-53. PubMed ID: 25646808
[TBL] [Abstract][Full Text] [Related]
28. Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.
Bachawal SV; Wali VB; Sylvester PW
BMC Cancer; 2010 Mar; 10():84. PubMed ID: 20211018
[TBL] [Abstract][Full Text] [Related]
29. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
30. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells.
Greenblatt DY; Vaccaro AM; Jaskula-Sztul R; Ning L; Haymart M; Kunnimalaiyaan M; Chen H
Oncologist; 2007 Aug; 12(8):942-51. PubMed ID: 17766653
[TBL] [Abstract][Full Text] [Related]
31. Interaction between microRNA-181a and TNFAIP1 regulates pancreatic cancer proliferation and migration.
Zhang P; Guo Z; Hu R; He X; Jiao X; Zhu X
Tumour Biol; 2015 Dec; 36(12):9693-701. PubMed ID: 26152285
[TBL] [Abstract][Full Text] [Related]
32. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
33. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway.
Yang L; Lin S; Kang Y; Xiang Y; Xu L; Li J; Dai X; Liang G; Huang X; Zhao C
J Exp Clin Cancer Res; 2019 Jan; 38(1):31. PubMed ID: 30674340
[TBL] [Abstract][Full Text] [Related]
34. Valproic acid enhances the anti-tumor effect of pegylated interferon-α towards pancreatic cancer cell lines.
Sugimoto K; Shimada M; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Iwahashi S
Anticancer Res; 2014 Jul; 34(7):3403-9. PubMed ID: 24982347
[TBL] [Abstract][Full Text] [Related]
35. Reduced expression of miR‑205‑5p promotes apoptosis and inhibits proliferation and invasion in lung cancer A549 cells by upregulation of ZEB2 and downregulation of erbB3.
Jiang M; Zhong T; Zhang W; Xiao Z; Hu G; Zhou H; Kuang H
Mol Med Rep; 2017 May; 15(5):3231-3238. PubMed ID: 28350117
[TBL] [Abstract][Full Text] [Related]
36. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Lu YY; Jing DD; Xu M; Wu K; Wang XP
World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
[TBL] [Abstract][Full Text] [Related]
37. APIP, an ERBB3-binding partner, stimulates erbB2-3 heterodimer formation to promote tumorigenesis.
Hong SH; Lee WJ; Kim YD; Kim H; Jeon YJ; Lim B; Cho DH; Heo WD; Yang DH; Kim CY; Yang HK; Yang JK; Jung YK
Oncotarget; 2016 Apr; 7(16):21601-17. PubMed ID: 26942872
[TBL] [Abstract][Full Text] [Related]
38. The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin.
Kato K; Iwama H; Yamashita T; Kobayashi K; Fujihara S; Fujimori T; Kamada H; Kobara H; Masaki T
Oncol Rep; 2016 Mar; 35(3):1582-92. PubMed ID: 26708419
[TBL] [Abstract][Full Text] [Related]
39. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
[TBL] [Abstract][Full Text] [Related]
40. Ginsenoside Rg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of EGFR/PI3K/Akt signaling pathway.
Jiang J; Yuan Z; Sun Y; Bu Y; Li W; Fei Z
Biomed Pharmacother; 2017 Dec; 96():619-625. PubMed ID: 29035827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
